Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Fulcrum Therapeutics (FULC) Stock Price & Analysis
224 Followers
FULC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.43 - $13.70
Previous Close$7.25
Volume510.50K
Average Volume (3M)635.51K
Market Cap
$449.03M
Enterprise Value$223.63M
Total Cash (Recent Filing)$236.22M
Total Debt (Recent Filing)$10.82M
Price to Earnings (P/E)-4.6
Beta1.92
Next Earnings
May 14, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding61,935,171
10 Day Avg. Volume508,260
30 Day Avg. Volume635,512
Standard Deviation0.53
R-Squared0.05
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)160.08
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue89.10
Enterprise Value/Gross Profit79.73
Enterprise Value/Ebitda-2.27
Forecast
1Y Price Target
$13.29Price Target Upside78.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Fulcrum Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressFULC is progressing with a pivotal Phase 3 trial for losmapimod, aiming to submit a filing and secure approval, which could significantly impact the treatment landscape for rare diseases.
Financial StabilityThe company boasts a strong cash position, providing financial stability with a projected funding runway into 2026, instilling investor confidence in its long-term operations.
Market Expansion StrategyFULC's strategic planning includes launching losmapimod in the US market and establishing partnerships to reach patients internationally, enhancing the company's global footprint.
Bears Say
Data ReliabilityConcerns exist about the variability of RWS measurements due to factors like time of day, daily activities, fitness, and diet.
Measurement ConsistencyConcerns are noted about potential variability in the Reachable Workspace (RWS) measurements due to factors like time of day and patient physical condition.
Regulatory ChallengesPociredir hit an unexpected hiccup last year when the FDA placed a full clinical hold on the program due to safety concerns.
---
Ownership Overview
44.05% Insiders
15.01% Mutual Funds
9.69% Other Institutional Investors
31.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.43 and its highest was $13.70 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Currently, no data Available
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is May 14, 2024 which is in 20 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Feb 27, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.426 by $0.026.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -$0.44.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 61,935,170 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.426. Following the earnings report the stock price went up 4.625%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Among the largest hedge funds holding Fulcrum Therapeutics’s share is RA Capital Management. It holds Fulcrum Therapeutics’s shares valued at 78M.
---
Fulcrum Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.29 (78.63% Upside)
$13.29 (78.63% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 11.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $491.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.56%
12-Months-Change
Fundamentals
Return on Equity
-44.84%
Trailing 12-Months
Asset Growth
13.68%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
---
FULC Earnings Call
Q4 2024
0:00 / 0:00
---
FULC Stock 12 Months Forecast
Average Price Target
$13.29
▲(78.63% Upside)
Technical Analysis
Best Analysts Covering FULC
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+21.82%
reiterated a buy rating 2 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +21.82% per trade.
---